Molecular typing is based on molecular genetic testing and isn't nonetheless routinely readily available. Molecular subtypes and immunohistochemical surrogate markers from the tumors (HR, HER2, triple adverse) correlate in about 70%. The differentiation of luminal A and B subtypes by HR standing and proliferation markers like Ki-67 might be practic